A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer

NCT06532006 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

550

Enrollment

INDUSTRY

Sponsor class

Conditions

Gastroesophageal-junction Cancer
Monoclonal Antibody
Gastric Cancer
HER2-positive Gastric Cancer

Interventions

DRUG: HLX22
DRUG: Pembrolizumab
DRUG: Trastuzumab
DRUG: Oxaliplatin
DRUG: Capecitabine

Sponsor

Shanghai Henlius Biotech

Collaborators

[object Object]